Wolfe Research comments on Madrigal Pharmaceuticals (MDGL) M&A optimism 'makes strategic sense' for buyers
Wolfe Research analyst Andy Chen reiterated a Peerperform rating on Madrigal Pharmaceuticals (NASDAQ: MDGL)The analyst commented, "Last week, optimism of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)